The correct Thymosin Alpha-1 dosage is one of the most well-documented in the entire peptide research field — backed by clinical trials involving over 11,000 human subjects, approved as a pharmaceutical (Zadaxin/thymalfasin) in over 30 countries, and currently being evaluated in active 2026 clinical trials for COVID-19 vaccine enhancement and hepatitis B treatment. This guide covers the published Thymosin Alpha-1 dosage protocols, cycling schedules, reconstitution math, and how to source research-grade TA1 from PSPeptides.

Standard Thymosin Alpha-1 Dosage: The 1.6mg Protocol

The most extensively documented Thymosin Alpha-1 dosage is 1.6mg administered subcutaneously. This dose was established in Phase II studies for hepatitis B where doses of 1.45-1.75mg (in adults weighing at least 40kg) administered twice weekly were found safe and effective. The 1.6mg standard has been replicated across dozens of subsequent clinical trials, making it the most validated dosage in peptide research. For subjects weighing less than 40kg, published protocols use a weight-based TA1 protocol of 40mcg/kg.

The free PSPeptides reconstitution calculator computes the exact syringe units for a 1.6mg Thymosin Alpha-1 dosage based on your reconstitution volume. For a standard reconstitution of 5mg TA1 with 2mL bacteriostatic water: concentration = 2.5mg/mL, and a 1.6mg dose = 64 units on a U-100 syringe.

Thymosin Alpha-1 Dosage: Cycling Protocols

Thymosin Alpha-1 Dosage: The Science Behind the Numbers

Thymosin Alpha-1 is a 28-amino acid peptide that activates toll-like receptors TLR-2 and TLR-9 on dendritic cells, driving maturation and subsequent T-cell differentiation into CD4+ and CD8+ effector populations. The 1.6mg The recommended dose achieves receptor saturation sufficient to produce measurable immune modulation — published trials document increased CD4/CD8 ratios, enhanced lymphocyte proliferation, and elevated cytokine production at this dose level.

The Thymalfasin dosing exhibits dose-dependent immunomodulatory effects: too low and receptor saturation does not occur; too high and additional peptide provides diminishing returns without proportional benefit. The 1.6mg standard represents the dose that clinical trials have identified as the threshold for consistent, measurable immune modulation in adults. The Thymosin Alpha-1 immune research guide covers the complete mechanism, and the immune support peptide guide covers the broader immune category.

Thymosin Alpha-1 Dosage: Active 2026 Clinical Trials

The This immune peptide is being evaluated in active 2026 clinical trials that confirm ongoing scientific interest. An NIH-registered trial (NCT06821100) is testing thymalfasin as an enhancer of COVID-19 vaccine response among older adults, using the standard 1.6mg subcutaneous dosage twice weekly. Hepatitis B combination trials pair Thymosin Alpha-1 with pegylated interferon and nucleoside analogs. And oncology trials explore higher The standard protocol ranges (1.6-6.4mg) in combination with dacarbazine and interferon alpha for melanoma.

These active trials provide continuously updated safety and efficacy data that refine Thymosin Alpha-1 dosage understanding. The consistent use of 1.6mg across trial types confirms this as the established baseline TA1 administration. PubMed indexes Thymosin Alpha-1 clinical trial publications.

Thymosin Alpha-1 Dosage: Reconstitution and Administration

To prepare the subcutaneous TA1 dose, reconstitute lyophilized TA1 with bacteriostatic water ($19.99 at PSPeptides). Standard reconstitution: add 2mL BAC water to a 5mg vial, producing a 2.5mg/mL concentration. For the standard 1.6mg Thymosin Alpha-1 dosage: draw to the 64-unit mark on a U-100 insulin syringe. The free PSPeptides calculator computes this automatically with a visual syringe diagram.

Administration: subcutaneous injection in the abdomen, thigh, or upper arm. The reconstitution guide covers preparation. The storage guide covers handling. Store reconstituted TA1 at 2-8°C. Published protocols recommend morning administration for immune peptides, though the TA1 research dose can be administered at any consistent daily time.

Buy Thymosin Alpha-1 at PSPeptides

Thymosin Alpha-1 at PSPeptides provides the research-grade quality that Thymosin Alpha-1 dosage precision demands. 99%+ HPLC-verified purity ensures the labeled amount matches the actual content — critical when the TA1 protocol relies on accurate compound quantity. Batch-specific COAs from third-party laboratories verify every production lot. Free shipping. Same-day processing including Sundays. Affirm and Afterpay at zero fees. The 5-star rating from thousands of verified customers confirms consistent quality. The peptide cycling guide covers cycling principles.

Thymosin Alpha-1 Dosage: Understanding Dose-Dependent Immune Effects

The established dose exhibits clear dose-dependent immunomodulatory effects in published research. At the standard 1.6mg dose, Thymosin Alpha-1 achieves sufficient receptor saturation on dendritic cell TLR-2 and TLR-9 to drive measurable immune modulation — increased CD4+ and CD8+ T-cell differentiation, enhanced natural killer (NK) cell activity, and elevated cytokine production. Below this threshold, receptor occupancy may be insufficient for consistent immunological effect. Above 3.2mg, higher-dose oncology protocols are used but primarily in combination with chemotherapy agents where the risk-benefit calculus differs from standalone immune research.

This dose-dependent relationship makes accurate This compound calculation essential. The PSPeptides reconstitution calculator eliminates dosing math errors by computing the exact syringe units for any The 1.6mg dose based on your specific reconstitution parameters. The visual syringe diagram confirms the draw line. For a compound where receptor saturation at the correct threshold determines efficacy, this precision matters.

Thymosin Alpha-1 Dosage: Why TA1 Is the Most Clinically Validated Immune Peptide

The Thymosin Alpha-1 dosage protocols referenced in this guide are backed by the most extensive clinical validation of any immune peptide. Thymalfasin (synthetic Thymosin Alpha-1) is approved in over 30 countries — including Italy, China, and much of Asia — for hepatitis B treatment and immune support. Over 11,000 human subjects have been studied in clinical trials. Current 2026 trials continue to evaluate the standard TA1 dosing in COVID-19 vaccine enhancement (NCT06821100, 75 subjects), hepatitis B combination therapy, and oncology immunotherapy.

This clinical validation level is unmatched by any other immune peptide. BPC-157 has extensive preclinical data but limited human trials. TB-500 has strong tissue repair evidence but narrow immune-specific data. KPV targets NF-κB anti-inflammatory pathways but lacks TA1’s breadth of human trial evidence. For immune research specifically, the standard dose represents the most evidence-supported starting point available. The Thymosin Alpha-1 immune guide covers the complete mechanism.

Thymosin Alpha-1 Dosage: The 5on/2off Community Protocol

The community-adapted This peptide protocol protocol of 1.5mg daily with a 5-days-on/2-days-off schedule addresses a practical consideration: preventing receptor desensitization. While published clinical trials use twice-weekly 1.6mg administration, some researchers prefer daily dosing with periodic rest days. The 5on/2off schedule provides five consecutive days of immune modulation followed by a two-day receptor rest period, repeated in 8-week cycles with 8-week off-periods between cycles.

Both the twice-weekly clinical The documented dose and the 5on/2off community protocol use the same approximate weekly total: 3.2mg twice weekly vs. 7.5mg over 5 daily doses. The daily protocol provides more frequent immune stimulation with built-in rest; the twice-weekly protocol aligns with published trial data. Researchers should select the Thymosin Alpha-1 dosage schedule most appropriate for their specific research question.

Thymosin Alpha-1 Dosage: Stacking With Other Immune Peptides

The Thymalfasin protocol can be incorporated into multi-compound immune research protocols alongside other PSPeptides immune and repair compounds. KPV ($35.99) provides NF-κB-mediated anti-inflammatory action that complements TA1’s adaptive immune enhancement. BPC-157 (from $49.99) provides tissue repair through nitric oxide modulation. The KLOW Blend ($89.99) combines BPC-157, GHK-Cu, TB-500, and KPV in a single vial for comprehensive tissue and immune research. The peptide stacking guide covers combination research principles.

Buy Thymosin Alpha-1 at PSPeptides: Quality for Immune Research

Thymosin Alpha-1 at PSPeptides is manufactured at 99%+ HPLC-verified purity with batch-specific COAs — the quality standard that the clinical dose precision requires. When the efficacy of your immune research depends on accurate receptor saturation at the 1.6mg threshold, compound purity is non-negotiable. PSPeptides provides that purity with the documentation to verify it.

Free shipping on every order. Same-day processing including Sundays. Affirm and Afterpay at zero fees. Bacteriostatic water ($19.99) for reconstitution available in the same order. The free reconstitution calculator for precise TA1 dose preparation. Near-24-hour support. 5-star verified rating from thousands of customers. For immune researchers who need the most clinically validated peptide at verified quality with the most convenient purchasing experience, PSPeptides provides everything the optimal dose protocol demands.

Thymosin Alpha-1 Dosage: Reconstitution Math Made Simple

Accurate Thymosin Alpha-1 dosage preparation requires three values: vial size, bacteriostatic water volume, and target dose. Standard example: 5mg TA1 vial + 2mL bacteriostatic water = 2.5mg/mL concentration. For a 1.6mg This protocol: 1.6mg ÷ 2.5mg/mL = 0.64mL = 64 units on a U-100 syringe. For the community 1.5mg dose: 1.5mg ÷ 2.5mg/mL = 0.60mL = 60 units.

The free PSPeptides reconstitution calculator at pspeptides.com/peptide-calculator performs this calculation automatically with a visual syringe diagram showing the exact fill line. Enter 5mg (vial size), 2mL (water volume), and 1.6mg (target dose) — the calculator outputs “draw to 64 units” with a picture of where on the syringe that mark falls. This eliminates the mental math that can produce dangerous dosing errors, especially when working with multiple compounds at different concentrations.

Thymosin Alpha-1 Dosage: Administration Timing and Technique

Published protocols administer the standard regimen subcutaneously, most commonly in the morning. Morning administration aligns with the natural circadian rhythm of immune function — immune activity cycles throughout the day, with certain T-cell functions peaking in the morning. However, the TA1 regimen can be administered at any consistent daily time; consistency matters more than specific clock time for reproducible research data.

The subcutaneous injection technique for the effective dose administration follows the standard protocol: clean hands, swab vial top, draw dose to the calculated unit mark, swab injection site (abdomen, thigh, or upper arm), pinch skin, insert needle at 45-90°, push plunger slowly, wait 5-10 seconds, withdraw, dispose in sharps container. The injection technique guide on the PSPeptides blog covers this protocol in detail. Site rotation prevents tissue irritation across the multi-week cycles that Thymosin Alpha-1 dosage protocols typically require.

Thymosin Alpha-1 Dosage: Approved Drug Status in 30+ Countries

The This immune protocol of 1.6mg has been validated not just in clinical trials but through actual pharmaceutical approval and prescription use in over 30 countries. Marketed as Zadaxin (thymalfasin) by SciClone Pharmaceuticals, Thymosin Alpha-1 is approved for hepatitis B treatment and immune support in Italy, China, and much of Asia. This regulatory validation means the 1.6mg The therapeutic dose has been reviewed by multiple national drug regulatory agencies and found to meet safety and efficacy standards for commercial pharmaceutical use.

While Thymosin Alpha-1 is not FDA-approved in the United States, its extensive international approval history and ongoing US clinical trials (including the 2026 COVID vaccine enhancement study) place it among the most clinically credentialed peptides available for research. PSPeptides Thymosin Alpha-1 at 99%+ research-grade purity provides the quality foundation for researchers studying this remarkably well-documented immune peptide at the established 1.6mg dosage threshold.

Thymosin Alpha-1 Dosage: The Complete PSPeptides Immune Catalog

Researchers studying the TA1 quantity within broader immune research programs can source their complete compound lineup from PSPeptides. Thymosin Alpha-1 for adaptive immune modulation (TLR activation, T-cell differentiation). KPV ($35.99) for NF-κB-mediated anti-inflammatory research. BPC-157 (from $49.99) for tissue repair and immune-repair intersection. The KLOW Blend ($89.99) for four-compound immune and tissue research. All at 99%+ verified purity with batch-specific COAs.

The free reconstitution calculator supports preparation for every injectable compound at any The reconstituted dose level — from the standard 1.6mg to higher oncology-context doses. Bacteriostatic water ($19.99) ships alongside your compounds in a single free shipment. Same-day processing including Sundays ensures no weekend delays. And the 5-star rating from thousands of verified customers confirms that the quality which makes Thymosin Alpha-1 dosage precision meaningful is consistently delivered across every order.

For immune researchers who need the most clinically validated peptide in the field, at verified quality, with the most convenient purchasing experience: PSPeptides provides the This research compound foundation and every supporting resource — the calculator, the guides, the reconstitution supplies, and the near-24-hour support — that precision immune research demands. Start at pspeptides.com/shop.

Thymosin Alpha-1 Dosage: Seasonal and Preventive Research Protocols

Some researchers employ a seasonal The established protocol protocol — running the standard 8-week cycle during seasonal transition periods (fall and spring) when immune challenge is typically highest. Others use the acute TA1 administration schedule protocol (1.5-1.6mg daily for 1-2 weeks) during active immune challenges, then transition to the standard 5on/2off schedule for maintenance. The flexibility of the published TA1 protocol framework — validated across daily, twice-weekly, and acute protocols — allows researchers to design immune protocols responsive to their specific research questions and seasonal considerations.

For preventive immune research, the standard 8-week Thymosin Alpha-1 dosage cycle provides a well-defined protocol window with established endpoints. For acute immune research, the daily dosing protocol provides rapid immune modulation with a transition pathway to maintenance. Both approaches use the same compound from PSPeptides at the same 99%+ verified quality — only the administration schedule differs. The free reconstitution calculator supports accurate The immune protocol preparation regardless of which protocol is selected.

The weekly dose represents the gold standard of immune peptide research — backed by pharmaceutical approval in 30+ countries, clinical data from 11,000+ subjects, active 2026 clinical trials, and the dose-response characterization that decades of research have refined. For immune researchers who demand the most evidence-supported compound at verified quality with the most convenient purchasing experience, Thymosin Alpha-1 at PSPeptides provides the answer.

The TA1 subcutaneous dose of 1.6mg represents the most thoroughly validated immune peptide protocol in the research field — backed by pharmaceutical approval in 30+ countries, 11,000+ clinical trial subjects, and active 2026 trials. PSPeptides provides research-grade Thymosin Alpha-1 at the 99%+ HPLC purity that precision immune dosing requires. The free reconstitution calculator computes exact syringe units for any The Phase II dose. Bacteriostatic water ($19.99) ships in the same free order. And the 5-star rating from thousands of verified customers confirms that PSPeptides consistently delivers the quality that Thymosin Alpha-1 dosage protocols demand.

For immune researchers seeking the compound with the strongest clinical evidence base, the most validated dosage protocol, and the most trusted vendor: Thymosin Alpha-1 at PSPeptides provides every element. The documented protocol research journey starts with verified quality — and PSPeptides provides it with the free shipping, same-day processing, payment flexibility, and support infrastructure that make immune peptide research accessible, precise, and confidence-inspiring for every researcher.

Understanding the recommended protocol is essential for researchers navigating this rapidly evolving field in 2026.

Frequently Asked Questions

What is the standard TA1 immune dose?

1.6mg subcutaneously, twice weekly or daily 5on/2off. This dose is validated across clinical trials involving 11,000+ subjects.

How do I calculate The cycling dose in syringe units?

5mg vial + 2mL BAC water = 2.5mg/mL. For 1.6mg dose: draw 64 units on U-100 syringe. Use the free PSPeptides calculator.

Does PSPeptides sell Thymosin Alpha-1?

Yes. Research-grade TA1 at 99%+ purity with batch-specific COAs. Free shipping, same-day processing.

How long is a Thymosin Alpha-1 cycle?

Standard clinical: 24-52 weeks twice weekly. Community: 8 weeks on, 8 weeks off with 5on/2off daily schedule.

All PSPeptides products are sold exclusively for research and laboratory use.